Recombinant erythroid Kruppel-like factor fused to GATA1 upregulates globin expr

与 GATA1 融合的重组红系 Kruppel 样因子上调珠蛋白 expr

• 批准号: 8557970
• 负责人: GRIFFIN RODGERS
• 金额: $ 70.74万
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8557970
• 关键词: Adult; Affect; Affinity; Binding; Binding Sites; Biological Assay; Blood; Bone Marrow Cells; Boxing; CD34 gene; Cell membrane; Cells; Characteristics; Chimeric Proteins; Clinical; Consensus; DNA Binding; DNA Binding Domain; DNA Sequencing Facility; DNA-Binding Proteins; Development; Disease; Erythrocytes; Erythroid Cells; Erythropoiesis; Fetal Hemoglobin; Fingers; GATA1 gene; Gene Expression; Genes; Genetic; Globin; Hemoglobin; Hemoglobin A; Hemoglobin A2; Hemoglobinopathies; Hemolytic Anemia; Hereditary Disease; Hour; Human Genetics; K-562; K562 Cells; Lead; Link; MEL Gene; Minor; Mutate; Mutation; Point Mutation; Population; Production; Promoter Regions; Public Health; RNA; Recombinants; Reporting; Series; Severity of illness; Sickle Cell; Sickle Cell Anemia; Sickle Hemoglobin; Site; Testing; Thalassemia; Therapeutic; Transactivation; Transcript; Transfection; Transfusion; Western Blotting; Zinc Fingers; base; cellular transduction; chromatin immunoprecipitation; erythroid Kruppel-like factor; flexibility; global health; hemoglobin A2' ; hydroxyurea; in vivo; mortality; polymerization; preclinical evaluation; prevent; promoter; protein expression; restoration; sickle deoxyhemoglobin; tool; transcription factor; vector

The β-hemoglobinopathies sickle cell disease and β-thalassemia are among the most common human genetic disorders worldwide. Hemoglobin A2 (HbA2, α2δ2) and fetal hemoglobin (HbF, α2γ2) both inhibit the polymerization of hemoglobin S that results in erythrocyte sickling. Expression of erythroid Kruppel-like factor (EKLF) and GATA1 is critical for transitioning hemoglobin from HbF to hemoglobin A (HbA, α2β2) and HbA2. The lower levels of δ-globin expression compared with β-globin expression seen in adulthood are likely due to the absence of an EKLF-binding motif in the δ-globin proximal promoter. In an effort to upregulate δ-globin to increase HbA2 expression, we created a series of EKLF-GATAl fusion constructs composed of the transactivation domain of EKLF and the DNA-binding domain of GATAl and then tested their effects on hemoglobin expression. EKLF-GATAl fusion proteins activated δ-, γ-, and β-globin promoters in K562 cells, and significantly upregulated δ- and γ-globin RNA transcripts and proteins expression in K562. We found that the expression of long-form EKLF-GATA1 increased δ-, γ-, and β-globin promoter activity 1.7-, 2.2-, and 6.8-fold, respectively, at 24 hours after transfection, and 5.4-, 2.9-, and 9.4-fold, respectively, at 48 hours after transfection (when compared with mock transfection). The effect of medium-form EKLF-GATA1 expression on globin promoter activity was less profound than that of long-form EKLF-GATA1, with a 1.9-fold increase for γ-globin promoter activity at 24 hours and a 2.5- and 3.2-fold increase for δ- and γ-globin promoter activity, respectively, at 48 hours. Both the short-form EKLF-GATA1 and vector only had no appreciable effect on globin promoter activity after 24 or 48 hours. GATA1 expression increased δ-globin promoter activity approximately 2-fold at 24 hours and 4.3-fold at 48 hours; EKLF induced β-globin promoter activity approximately 2-fold at both 24 and 48 hours. These results indicate the long- and medium-form of EKLF-GATA1 fusion proteins, which contain the N-finger and C-finger of the GATA1-binding domain, may well bind to and activate the δ-globin promoter. In contrast, the short-form of EKLF-GATA1 fusion protein, which lacked the intact C-finger, was not able to bind to the δ-globin promoter and thus had no impact on globin expression. In CD34+ cells, tThe long-form EKLF-GATA1 upregulated β-globin expression 1.7-fold, δ-globin gene expression 2.7-fold, and γ-globin gene expression 1.9-fold. The medium-form EKLF-GATA1 upregulated δ-globin gene expression 2.2-fold and γ-globin 1.3-fold, but had no effect on β-globin gene expression. We also observed that EKLF only-transduced CD34+ cells expressed 1.4-fold higher levels of β-globin expression, and GATA1 only-transduced cells expressed 1.5-fold higher levels of δ-globin and 1.3-fold higher levels of β-globin. In contrast, the short-form of EKLF-GATA1 had no significant effect on globin expression. The results of gene expression were confirmed in both K562 and CD34+ cells, in Western Blot analysis. The binding of EKLF-GATA1 fusion proteins at the GATA1 consensus site in the δ-globin promoter was confirmed by chromatin immunoprecipitation assay. In summary, we present two functional EKLF-GATA1 fusion proteins containing the GATA1 primary binding domain that could bind to and activate δ-globin promoter and significantly increase δ-globin expression in K562 cells and CD34+ bone marrow cells. Although the long-form EKLF-GATA1 fusion protein also increased β-globin expression in CD34+ cells, its major effects were on δ- and γ-globin induction; the medium-form EKLF-GATA1 elevated δ- and γ-globin expression without an effect on β-globin expression. Induction of both δ- and γ-globin expression may be beneficial for an antisickling effect and compensating for impaired β-globin production. These EKLF-GATA1 fusion proteins could prove useful as a genetic therapeutic tool for SCD and β-thalassemia, and warrant further preclinical evaluation in vivo.

β-血红蛋白病镰状细胞疾病和β-甲无血症是全球最常见的人类遗传疾病之一。血红蛋白A2（HBA2，α2δ2）和胎儿血红蛋白（HBF，α2γ2）都抑制血红蛋白S的聚合，从而导致红细胞肉体的红细胞。红花样因子（EKLF）和GATA1的表达对于将血红蛋白从HBF转变为血红蛋白A（HBA，α2β2）和HBA2至关重要。与成年中看到的β-珠蛋白表达相比，Δ-珠蛋白表达的较低水平可能是由于Δ-珠蛋白近端启动子中缺乏EKLF结合基序。为了上调δ-珠蛋白增加HBA2表达，我们创建了一系列由EKLF的反式激活结构域和Gatal的DNA结合结构域组成的EKLF-GATAL融合构建体，然后测试了它们对血红蛋白表达的影响。 EKLF-gatal融合蛋白在K562细胞中激活了δ-，γ-和β-珠蛋白启动子，并在K562中显着上调δ-和γ-格洛比蛋白RNA转录物以及蛋白质的表达。我们发现，长形EKLF-GATA1的表达分别增加了δ-，γ-和β-珠蛋白启动子活性在转染后24小时，分别为5.4-，2.9-和9.4倍，分别为1.7-，2.2-和6.8倍，分别在转置后48小时（与止枪转染相比）。中等形式的EKLF-GATA1表达对球蛋白启动子活性的影响不如长格式EKLF-GATA1的影响，在24小时时γ-蛋白启动子活性增加了1.9倍，在48小时时，γ-蛋白启动子活性增加了2.5和2.5和3.2倍。短形式的EKLF-GATA1和载体在24或48小时后仅对球蛋白启动子活性没有明显的影响。 GATA1表达在24小时时增加了约2倍，在48小时时增加了4.3倍； EKLF在24和48小时内诱导β-球蛋白启动子活性约2倍。这些结果表明，含有GATA1结合结构域的N手指和C手指的EKLF-GATA1融合蛋白的长和中型可以很好地结合并激活δ-珠蛋白启动子。相反，缺乏完整的C指定的EKLF-GATA1融合蛋白的短形式无法与δ-珠蛋白启动子结合，因此对球蛋白表达没有影响。在CD34+细胞中，长形式的EKLF-GATA1上调了β-珠蛋白表达1.7倍，δ-珠蛋白基因表达2.7倍2.7倍和γ-球蛋白基因表达1.9倍。中型EKLF-GATA1上调了δ-珠蛋白基因表达2.2倍和γ-球蛋白1.3倍，但对β-珠蛋白基因表达没有影响。我们还观察到，仅EKLF转导的CD34+细胞表达了1.4倍的β-珠蛋白表达水平高1.4倍，而仅GATA1仅通过tha transdDAS的细胞表达了1.5倍Δ-氯丁蛋白水平高1.5倍，β-蛋白水平高1.3倍。相反，EKLF-GATA1的短形式对球蛋白表达没有显着影响。 在Western印迹分析中，在K562和CD34+细胞中证实了基因表达的结果。通过染色质免疫沉淀测定法证实了EKLF-GATA1融合蛋白在δ-珠蛋白启动子中GATA1共有位点上的结合。总而言之，我们介绍了两个功能性EKLF-GATA1融合蛋白，其中含有GATA1主要结合结构域，它们可以与K562细胞和CD34+ CD34+骨髓细胞中的δ-珠蛋白启动子结合和激活。尽管长形式的EKLF-GATA1融合蛋白也增加了CD34+细胞中β-珠蛋白的表达，但其主要作用对δ-和γ-球蛋白诱导均具有主要作用。中型EKLF-GATA1升高δ-和γ-球蛋白表达，对β-珠蛋白表达的影响没有影响。诱导δ-和γ-球蛋白表达的诱导可能有益于抗分解作用并补偿受损的β-珠蛋白产生。这些EKLF-GATA1融合蛋白可能被证明可作为SCD和β-甲性甲性疾病的遗传治疗工具，并保证在体内进一步的临床前评估。